No change in small low-density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial.
作者信息
Hirano Tsutomu
机构信息
Diabetes Center, Ebina General Hospital, Kanagawa, Japan.
出版信息
J Diabetes Investig. 2023 Apr;14(4):630-631. doi: 10.1111/jdi.13983. Epub 2023 Jan 27.
Abstract
摘要
相似文献
1
No change in small low-density lipoprotein cholesterol levels with pemafibrate might explain the negative results of the PROMINENT trial.匹伐他汀对小而密低密度脂蛋白胆固醇水平无影响，这可能解释了PROMINENT试验的阴性结果。
J Diabetes Investig. 2023 Apr;14(4):630-631. doi: 10.1111/jdi.13983. Epub 2023 Jan 27.
2
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.用佩马弗他酯降低甘油三酯以降低心血管风险。
N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.
3
Combination therapy with pemafibrate (K-877) and pitavastatin improves vascular endothelial dysfunction in dahl/salt-sensitive rats fed a high-salt and high-fat diet.联合应用 pemafibrate（K-877）和匹伐他汀可改善盐敏感性 Dahl 大鼠在高盐高脂饮食下的血管内皮功能障碍。
Cardiovasc Diabetol. 2020 Sep 26;19(1):149. doi: 10.1186/s12933-020-01132-2.
4
Effects of pemafibrate (K-877) on cholesterol efflux capacity and postprandial hyperlipidemia in patients with atherogenic dyslipidemia.贝特类药物 K-877 对伴有动脉粥样硬化性血脂异常患者胆固醇流出能力和餐后血脂异常的影响。
J Clin Lipidol. 2018 Sep-Oct;12(5):1267-1279.e4. doi: 10.1016/j.jacl.2018.06.010. Epub 2018 Jun 26.
5
6
Efficacy and Safety of Pemafibrate Versus Fenofibrate in Patients with High Triglyceride and Low HDL Cholesterol Levels: A Multicenter, Placebo-Controlled, Double-Blind, Randomized Trial.贝特类药物在高甘油三酯血症和低高密度脂蛋白胆固醇血症患者中的疗效和安全性：一项多中心、安慰剂对照、双盲、随机试验。
J Atheroscler Thromb. 2018 Jun 1;25(6):521-538. doi: 10.5551/jat.44412. Epub 2018 Apr 7.
7
Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.降脂药物联合治疗对冠心病且胆固醇水平“正常”患者的影响。一项随机、安慰剂对照试验。哈佛动脉粥样硬化逆转项目（HARP）研究组。
Ann Intern Med. 1996 Oct 1;125(7):529-40. doi: 10.7326/0003-4819-125-7-199610010-00001.
8
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.非诺贝特和依折麦布单药治疗及联合用药对混合型高脂血症患者脂蛋白亚组分内胆固醇质量和低密度脂蛋白峰值粒径的影响。
Metabolism. 2008 Jun;57(6):796-801. doi: 10.1016/j.metabol.2008.01.026.
9
Low-density lipoprotein size and subclasses are markers of clinically apparent and non-apparent atherosclerosis in type 2 diabetes.低密度脂蛋白大小和亚类是2型糖尿病中临床显性和非显性动脉粥样硬化的标志物。
Metabolism. 2005 Feb;54(2):227-34. doi: 10.1016/j.metabol.2004.08.017.
10
The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.高脂肪高果糖仓鼠作为烟酸在人体中生物活性的动物模型。
Metabolism. 2013 Dec;62(12):1840-9. doi: 10.1016/j.metabol.2013.08.001. Epub 2013 Sep 13.
引用本文的文献
1
Effects of Pemafibrate on Cardio-Ankle Vascular Index (CAVI) in Patients with Type 2 Diabetes or Ischemic Heart Disease: A 24-Week Observational Study.匹伐他汀对2型糖尿病或缺血性心脏病患者心踝血管指数（CAVI）的影响：一项为期24周的观察性研究。
Vasc Health Risk Manag. 2025 Apr 24;21:293-304. doi: 10.2147/VHRM.S506642. eCollection 2025.
2
Clinical significance of small dense low-density lipoprotein cholesterol measurement in type 2 diabetes.2型糖尿病中小而密低密度脂蛋白胆固醇检测的临床意义
J Diabetes Investig. 2025 Mar;16(3):370-383. doi: 10.1111/jdi.14398. Epub 2025 Jan 7.
3
Lessons from PROMINENT and prospects for pemafibrate.从 PROMINENT 研究中获得的启示和 pemafibrate 的前景。
Cardiovasc Diabetol. 2024 Jul 29;23(1):279. doi: 10.1186/s12933-024-02305-z.
4
The chylomicron saga: time to focus on postprandial metabolism.乳糜微粒传奇：是时候关注餐后代谢了。
Front Endocrinol (Lausanne). 2024 Jan 18;14:1322869. doi: 10.3389/fendo.2023.1322869. eCollection 2023.
5
Prospective randomized comparative study of the effect of pemafibrate add-on or double statin dose on small dense low-density lipoprotein-cholesterol in patients with type 2 diabetes and hypertriglyceridemia on statin therapy.前瞻性随机对照研究在他汀类药物治疗的 2 型糖尿病伴高甘油三酯血症患者中小而密低密度脂蛋白胆固醇的依折麦布附加或加倍他汀剂量的效果。
J Diabetes Investig. 2023 Dec;14(12):1401-1411. doi: 10.1111/jdi.14076. Epub 2023 Aug 30.
6
Hypertriglyceridemia contributes significantly to high prevalence of small dense LDL-cholesterol in patients with type 2 diabetes, even when LDL-C targets are achieved.即使低密度脂蛋白胆固醇（LDL-C）目标已达成，高甘油三酯血症仍在2型糖尿病患者小而密低密度脂蛋白胆固醇的高患病率中起重要作用。
Diabetol Int. 2023 May 15;14(3):288-293. doi: 10.1007/s13340-023-00634-0. eCollection 2023 Jul.
7
Dietary Effects on Monocyte Phenotypes in Subjects With Hypertriglyceridemia and Metabolic Syndrome.饮食对高甘油三酯血症和代谢综合征患者单核细胞表型的影响。
JACC Basic Transl Sci. 2023 Apr 26;8(5):460-475. doi: 10.1016/j.jacbts.2023.02.011. eCollection 2023 May.
8
The influence of triglycerides on small dense low-density lipoprotein cholesterol levels is attenuated in low low-density lipoprotein-cholesterol range: Implications for the negative results of the PROMINENT trial.在低 LDL-胆固醇范围内，甘油三酯对小而密 LDL 胆固醇水平的影响减弱：对 PROMINENT 试验阴性结果的影响。
J Diabetes Investig. 2023 Jul;14(7):902-906. doi: 10.1111/jdi.14013. Epub 2023 Apr 4.
本文引用的文献
1
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.用佩马弗他酯降低甘油三酯以降低心血管风险。
N Engl J Med. 2022 Nov 24;387(21):1923-1934. doi: 10.1056/NEJMoa2210645. Epub 2022 Nov 5.
2
A New Equation Based on the Standard Lipid Panel for Calculating Small Dense Low-Density Lipoprotein-Cholesterol and Its Use as a Risk-Enhancer Test.一种基于标准脂质谱计算小而密低密度脂蛋白胆固醇的新方程及其作为风险增强试验的应用。
Clin Chem. 2021 Jul 6;67(7):987-997. doi: 10.1093/clinchem/hvab048.
3
Detailed analysis of lipolytic enzymes in a Japanese woman of familial lipoprotein lipase deficiency - Effects of pemafibrate treatment.对一名家族性脂蛋白脂肪酶缺乏症日本女性脂解酶的详细分析——匹伐他汀治疗的效果
Clin Chim Acta. 2020 Nov;510:216-219. doi: 10.1016/j.cca.2020.07.031. Epub 2020 Jul 17.
4
Development of a homogeneous assay for measurement of small dense LDL cholesterol.开发一种用于测量小而密 LDL 胆固醇的均相测定法。
Clin Chem. 2011 Jan;57(1):57-65. doi: 10.1373/clinchem.2010.149559. Epub 2010 Nov 4.
Zotero 插件